Male genital vitiligo: Topical tofacitinib and 308 nm excimer light combination treatment – Retrospective analysis of efficacy and safety

Objectives: Vitiligo is a common depigmenting condition that carries a high psychosocial and sexual morbidity when it affects genitalia. Male genital vitiligo represents a specific challenge. Topical ruxolitinib and other topical Janus Kinase inhibitors have shown promising repigmenting efficacy in treating mucosal vitiligo with or without 308 nm excimer light. The aim of this study was to analyze the efficacy and safety of topical tofacitinib with 308 nm excimer light therapy in the management of male genital vitiligo retrospectively in a case series of 15 patients. Material and Methods: Total 15 male patients having genital vitiligo who were treated with tofacitinib ointment 2% with 308 nm excimer lamp were analyzed. The initial dose of 50 mj/cm 2 of excimer lamp was given covering the surrounding normal area. The dose was gradually increased by 20 mj/cm 2 every week up to 350–400 mj/cm 2 twice a week. The treatment was continued till complete repigmentation of the lesions. Results: All patients tolerated the treatment well. Complete repigmentation took place after 16–20 weeks of treatment with 30–35 sessions of 308 nm excimer lamp in majority of the patients (11 out of 15) while remaining individuals need another 8–10 sessions. There was no recurrence post 6 months of completion of treatment. Conclusion: Topical tofacitinib with 308 nm excimer light therapy is found effective and safe in the management of male genital vitiligo.